ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) clearance of CarriGen® Porous Bone Substitute Material. CarriGen is available for immediate sale through ETEX's independent sales force. CarriGen builds upon the clinically proven benefit of ETEX nanocrystalline calcium phosphate technology by adding the advantage of increased porosity and pore size. CarriGen is the first highly porous bone graft substitute that sets hard upon implantation for a complete defect fill.
CarriGen is indicated as a bone void filler of the pelvis, extremities and spine, including posterolateral spine fusion.
Cleared to be hydrated with saline or blood, CarriGen viscous putty may be injected or molded to pack into a defect. Upon implantation, CarriGen sets hard to provide compressive strength comparable to cancellous bone. The resulting osteoconductive scaffold provides interconnected porosity that facilitates cell mediated remodeling at the same rate as the surrounding bone. The proprietary nanocrystalline calcium phosphate technology, which serves as the foundation of the osteoconductive scaffold, has proven to be safe and effective in more than 10,000 implantations and a landmark Level 1 clinical trial.